Angelini Ventures Managing Director Tanja Dowe joins Hypervision Surgical's Board of Directors
Rome, Italy, 29 April 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, is participating in Hypervision Surgical's oversubscribed £17 million Series A round. Hypervision Surgical ("Hypervision") is a UK-based pioneer in real-time hyperspectral imaging for surgery.
The funding, led by Heal Capital with participation from Angelini Ventures, IP Group, and Daycrest among others, aims to accelerate the commercial deployment of Hypervision's Hyperspectral Intelligence® platform, expanding its clinical adoption and transforming the company's next-generation hyperspectral sensing technology, co-developed with Imec, a global leader in the development of semiconductor and spectral sensing technologies, in a scalable, cloud-enabled platform for AI-assisted surgery.
The Hyperspectral Intelligence® imaging platform captures information beyond what the human eye, and conventional surgical cameras, can perceive. By combining hyperspectral sensing with AI-driven analytics, the technology enables real-time, quantitative insights into tissue physiology during surgery. This has the potential to fundamentally improve intraoperative decision-making, reduce complications, and establish a new data-driven standard for surgical care.
The company's goal is to integrate Hyperspectral Intelligence® into laparoscopic, robotic, microscopic and endoscopic surgical platforms, making it possible to read more accurately the data in the hundreds of millions of surgeries performed each year.
Michael Ebner, CEO and Co-Founder of Hypervision Surgical, said: "This Series A marks a major milestone in our mission to power surgical intelligence ...
